Pfizer Reports the P-III Trial Data of Fordadistrogene Movaparvovec for Duchenne Muscular Dystrophy
Shots:
- The P-III (CIFFREO) study investigates the safety and effectiveness of fordadistrogene movaparvovec vs PBO among ambulatory boys (4 to 7yrs.) with DMD on a stable daily regimen of glucocorticoids
- The study did not reach the 1EP & 2EP of change in the North Star Ambulatory Assessment (NSAA) total score at 1yr. as well as 10-meter run/walk velocity & time to rise from floor velocity, respectively
- The safety profile showed manageable mild to moderate AEs and treatment-related SAEs responsive to clinical management. Pfizer is keeping a check on patients and assessing further steps for the trial
Ref: Pfizer | Image: Pfizer
Related News: Pfizer to Initiate P-III Study of Fordadistrogene Movaparvovec After FDA Lift Clinical Hold
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
